Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer
- 15 February 2019
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 25 (4) , 1139-1141
Abstract
Castration-resistant prostate cancer is characterized by loss of the androgen inactivation enzyme HSD17B2, emphasizing the importance of intratumoral androgens in tumor progression. Inactive isoforms generated by alternative splicing destabilize the wild-type enzyme, adding steroidogenesis to other prostate cancer drivers that undergo oncogenic splicing, highlighting aberrant splicing as a therapeutic target. See related article by Gao et al., p. 1291Keywords
Funding Information
- HHS | NIH | National Cancer Institute (NCI) (P50 CA97186)
- HHS | NIH | National Cancer Institute (NCI) (P01 CA163227)
- U.S. Department of Defense (DOD) (W81XWH-12-1-0208)
This publication has 6 references indexed in Scilit:
- Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease ProgressionClinical Cancer Research, 2019
- Alternative splicing in prostate cancerNature Reviews Clinical Oncology, 2018
- Targeting Splicing in Prostate CancerInternational Journal of Molecular Sciences, 2018
- Loss of an Androgen-Inactivating and Isoform-Specific HSD17B4 Splice Form Enables Emergence of Castration-Resistant Prostate CancerCell Reports, 2018
- Steroid hormone synthetic pathways in prostate cancer2013
- Alternative Splicing Programs in Prostate CancerInternational Journal of Cell Biology, 2013